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SHORT COMMUNICATION

Diagnostic Accuracy of Anti-Endomysial
Antibody in Celiac Disease

ABSTRACT

Arslaan Javaeed1, Walayat Shah2, Sanniya Khan Ghauri3 and Rizwan Akhtar1

The objective of the study was to determine the diagnostic accuracy of anti-EMA antibody in comparison to
histopathological findings in patients suspected of CD. This cross-sectional study was conducted at Gastroenterology
Department, Fatima Memorial Hospital, Lahore, from March to October 2014. One hundred and twenty-one patients aged
between 5 - 60 years of either gender were recruited in the study. Every patient went through serological testing and
biopsy specimens were obtained from second part of the duodenum. Histopathological evaluation was done according to
the Modified Marsh classification. The overall sensitivity of anti-EMA came out to be 85.7% which varied with the
histological lesions being 75.0%, 83.3%, and 100% for Marsh IIIA, IIIB and IIIC, respectively. Although anti-EMA has high
sensitivity but serological tests as a sole mean of diagnosis are currently unable to replace the biopsy.
Key Words: Celiac disease. Anti-endomysial antibody. Duodenal biopsy. Marsh classification.

Celiac disease (CD) is precipitated by consuming food
which contains gluten in genetically susceptible
individuals. Its diagnosis still remains challenging. Its
prevalence varies from 2 to 13%.1 The combination of
environmental, genetic factors, and immunological
mechanisms is involved in activation and progression of
celiac disease.2 Serological tests for diagnosing CD
include antigliadin antibody (AGA), anti-tissue transglutaminase (anti-tTG) antibody, and anti-endomysial
antibody (anti-EMA).3,4 However, in children less than 2
years of age the performance of AGA is far better than
anti-EMA and anti-tTG antibodies.5,6 Anti- EMA and antitTG are considered as the serological tests of choice
these days in adults as they are more sensitive. Tissue
biopsy is regarded as gold standard of diagnosing CD.7
In Pakistan, scanty data is available on celiac disease
and its criteria for diagnosis. This study was aimed to
determine the diagnostic accuracy of anti-EMA antibody
test in comparison to histopathological findings graded
according to Modified Marsh classification in patients
suspected of celiac disease.
It was a cross-sectional study carried out from March to
October 2014 in the Department of Gastroenterology,
Fatima Memorial Hospital, Shadman, Lahore, Pakistan.
The sample included 121 patients of either gender, ages
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ranging from 5 to 60 years coming to the outpatient
department and clinically suspected of celiac disease.
Extremes of ages, having any other comorbid conditions
etc. and previously diagnosed celiac patients, were
excluded from the study. Formal consent from each
patient or the guardian, in case of children, was taken
before inclusion into the study. The whole study was
performed according to Ethical Principles for Medical
Research outlined in the Helsinki Declaration (revised in
2000). The study was approved by the Ethical Review
Board of Khyber Medical University, Peshawar and
Fatima Memorial Hospital, College of Medicine and
Dentistry, Lahore.

Small bowel biopsies and blood samples were taken
from these patients at the endoscopic unit of Department
of Gastroenterology. Histopathological examination was
conducted at the Hospital's Pathology Unit and
serological tests, i.e. anti-EMA test and total IgA etc.,
were carried out in a community based laboratory. Data
including age, gender, complete clinical history, and
mode of presentation were collected. The serological
test for anti-EMA was performed on each blood sample
through commercial kit in accordance with guidelines
provided by the manufacturer (D-Tek, Blue Well, Mons,
Belgium).

For every case, duodenal biopsy samples were placed
in clearly labelled, separate specimen collection jars.
Duodenal biopsy specimens were fixed in buffered
formalin and embedded in paraffin wax. Standard 3 - 5 µm
thick sections were stained with hematoxylin and eosin
and the slides were examined by two independent
pathologists blinded to the serology reports of those
patients. No inter-observer variation was reported.
Villous atrophy and crypt hyperplasia were documented
according to the modified Marsh classification. CD3
marker was used for visualization of intra-epithelial
lymphocytes (Table I).

Journal of the College of Physicians and Surgeons Pakistan 2016, Vol. 26 (6): 541-542

541

Arslaan Javaeed, Walayat Shah, Sanniya Khan Ghauri and Rizwan Akhtar

Table I: Modified Marsh classification.
Stages

IEL* per 100 enterocytes

Crypts

1

More than 30

Normal

0
2

3a

b
c

Less than 30

More than 30

More than 30

Villi

Normal

Normal

Increased

Normal

Normal

Increased

More than 30

Mild atrophy

Increased

More than 30

Marked atrophy

Increased

*Intra-epithelial lymphocytes

Absent

Table II: Celiac disease on anti-EMA versus histopathology-cross
tabulation.
Celiac disease on anti-EMA

Celiac disease on histopathology
Positive

Negative

% of celiac disease on

85.7%

14.3%

Positive predictive value

92.3%

% of celiac disease on

0.9%

Count

anti-EMA (sensitivity)
Count

anti-EMA (specificity)

Negative predictive value
Count

12

2

14

1

106

99.1%
98.1%
107

Sensitivity =85.7%, Specificity=99.1%, PPV=92.3, NPV=98.1%, Accuracy= 97.5%

Total
13

100.0%

108

100.0%

121

Sample size was calculated as 121 patients, using WHO
formula, with a prevalence rate of 13%, margin of error
6% and a confidence interval of 95%. Study variables
were the age, gender, serology and histopathology for
celiac disease. Mean ± standard deviation for the age of
patients, frequency and percentage were calculated.
Sensitivity, specificity, positive predictive values (PPV)
and negative predictive values (NPV) were determined
by taking histopathology as gold standard. Data was
analyzed by using SPSS software version 16.

The mean age of patients was 30.24 ±9.00 years.
Eighty-seven (71.9%) patients were females and 34
(28.1%) were males. No patient was found to have IgA
deficiency. The frequency of CD in this study was 11.6%
(14/121) on histopathology. The total patients positive for
celiac disease on anti-EMA test were 13 (true positives
12, false positive 1) and 108 patients were negative for
anti-EMA test (true negatives 106, false negatives 2,
Table II). Among the CD patients 85.7% (12/14) tested
positive for anti-EMA and 14% (2/14) yielded negative
results for anti-EMA. On the other hand 99.1% (106/107)
of non-CD were negative and 0.9% (1/107) came out to
be positive for anti-EMA. The overall sensitivity and
specificity of anti-EMA were 85.7% and 99.1%. The PPV
and NPV came out to be 92.3% and 98.1%, respectively
(Table II). Out of 14 patients diagnosed for CD on
intestinal biopsy, 3 patients showed Marsh IIIA, 5
patients exhibited Marsh IIIB, and 6 patients had Marsh
IIIC lesions. The sensitivity of anti-EMA antibody for
Marsh IIIA, IIIB and IIIC was 75.0%, 83.3% and 100%,
respectively.
As compared to the other studies, the sensitivity of antiEMA test for total villous atrophy (VA) in this study was
100% as reported by Rostami et al. but the sensitivity of
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anti-EMA test for partial VA in this study was 75.0%
(Marsh IIIA) to 80 % (Marsh IIIB), which is considerably
higher than the disappointing 31% (Marsh IIIA) as
documented by them.8 A similar study by Tarmure et al.
concluded that anti-EMA had a lower sensitivity in
patients with Marsh-I and Marsh II lesions.9

This is the first study conducted in Pakistan which
determined the accuracy of anti-EMA test against
histopathology in diagnosing CD. Studies done
previously were mostly on clinical presentation of celiac
disease and diagnosis through anti-tTG.10 In Pakistan,
even large established laboratories in cosmopolitan
cities such as Lahore and Karachi are not providing the
facilities of highly specific and sensitive IgA-EMA testing.
Taking the diagnostic accuracy in consideration, it is
highly recommended that it should be used along with
anti-tTG antibody test.
It is concluded that the serological test as a sole mean
of diagnosis is currently unable to replace the intestinal
biopsy as its sensitivity varies with the grading of
histological lesions. Therefore, when the symptoms of
celiac disease persist and patient is reported
seronegative for the antibody, still an intestinal biopsy is
necessary to avoid missing the disease.
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